California-based Exelixis, a specialty manufacturer with two high-priced drug products on the market, announced it is further restricting contract pharmacy access to 340B hospitals in a May 31 letter published on 340B ESP.
Swedish biopharmaceutical company Sobi announced this week that beginning July 1 it will implement 340B contract pharmacy restrictions, making the [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
